Europe Approves GSK’s Blenrep for Relapsed and Refractory Multiple Myeloma

The European Commission has approved GlaxoSmithKline’s (GSK) Blenrep (belantamab mafodoin) to treat patients with relapsed and refractory multiple myeloma who have received at least four prior therapies.

The approval is based on a phase 2 clinical trial, in which treatment with Blenrep administered as a 2.5 mg/kg dose every three weeks resulted in a 32 percent overall response rate. Median duration of response in the trial was 11 months, and median overall survival was 13.7 months.

The European approval follows the FDA’s approval of the drug earlier this month for the same indication.